Dr. Shalaby’s research interests include utilization of implantable devices for and biomarkers of risk for sudden cardiac death as well as utilization of devices for assessment and treatment of congestive heart failure and sleep related breathing disorders.
Dr. Shalaby practices cardiology at UPMC Presbyterian. He has participated in clinical trials, including the Ranolazine Implantable Cardioverter-Defibrillator Trial, which looks at how effective the drug ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs); and the Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial which has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF).
- MD, Ain Shams University, Cairo, 1986
- Masters Degree in Internal Medicine, Ain Shams University, Cairo First Part, 1989
- Masters Degree in Internal Medicine, Ain Shams University, Cairo Second and Final Part, 1991
- Residency, Internal Medicine, Albert Einstein College of Medicine, 1994
- Fellowship, Cardiology, Creighton University, 1997
- Fellowship, Electrophysiology, UCLA Veterans Administration Medical Center, 1998
Education & Training
Belperio J, Horwich T, Abraham WT, Fonarow GC, Gorcsan J 3rd, Bersohn MM, Singh JP, Sonel A, Lee LY, Halilovic J, Kadish A, Shalaby AA. Inflammatory Mediators and Clinical Outcome in Patients With Advanced Heart Failure Receiving Cardiac Resynchronization Therapy. Am J Cardiology. 2016; 117(4): 617-25.
Wang NC, Singh M, Adelstein EC, Jain SK, Mendenhall GS, Shalaby AA, Voigt AH, Saba S. New-onset left bundle branch block-associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. Heart Rhythm. 2016; 13(4): 933-42.
Aleong RG, Mulvahill MJ, Halder I, Carlson NE, Singh M, Bloom HL, Dudley SC, Ellinor PT, Shalaby A, Weiss R, Gutmann R, Sauer WH, Narayanan K, Chugh SS, Saba S, London B. Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function. J Am Heart Assoc. 2015; 4(8): e001566.
Shariff N, Eby E, Adelstein E, Jain S, Shalaby A, Saba S, Wang NC, Schwartzman D. Response to Letter to the Editor. J Cardiovasc Electyrophysiol. 2015; 26(10): E13.
Shariff N, Eby E, Adelstein E, Jain S, Shalaby A, Saba S, Wang NC, Schwartzman D. Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation. J Cardiovasc Electrophysiol. 2015; 26(7): 783-9.
AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R, Bloom HL, Dudley SC, Ellinor PT, Saba SF, Shalaby A, Weiss R, McNamara DM, Halder I, London B. Genetic Risk Assessment of Defibrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol. 2015; 115(7): 924-31.
Shalaby AA, Abraham WT, Fonarow GC, Bersohn MM, Gorcsan J 3rd, Lee LY, Halilovic J, Saba S, Maisel A, Singh JP, Sonel A, Kadish A. Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients. Pacing Clin Electrophysiol. 2015; 38(5): 581-90.
Shalaby AA, Refaat M, Lacomis J, Zenati M. Post occlusive left atrial appendage thrombosis with extension into the left atrium. BMJ Case Report. 2014; May 21
Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, Groeneveld PW, Shalaby A, Dixit S. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met?. J Am Coll Cardiol. 2014; 63(22): 2388-94.
Shariff N, Singh M, Shalaby A. Acute disseminated intravascular coagulation following ICD lead extraction. BMJ Case Report. 2014; March 5
- Marquis' Who's Who of America, 2009
